During the corresponding time, Cyclo Therapeutics Inc saw a revenue deteriorated by -52.82 % year on year, sequentially revenue grew by 89.9 %. While revenue at the Cyclo Therapeutics Inc 's corporate clients
Cyclo Therapeutics Inc's Comment on Sales, Marketing and Customers
The company provides treatment for Niemann-Pick disease type C (NPC) under physician supervision through an FDA-approved Investigational New Drug protocol. The FDA grants orphan drug designation to drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the United States or where sales are unlikely to recover development costs. This designation offers benefits including tax credits and seven years of marketing exclusivity for the approved indication, which can affect the approval of competing products. The exclusivity applies solely to the designated indication and does not expedite the FDA review process. Additionally, the FDA offers expedited review programs such as fast track designation, accelerated approval, priority review, and breakthrough therapy designation to support drug development and approval.
Groundbreaking Progress in Niemann-Pick Disease Type C1 Treatment: Cyclo Therapeutics Reports Promising Data from Phase 3 Study In an age where biomedical innovation is key to developing effective treatments for rare and complex diseases, Cyclo Therapeutics, Inc. (Nasdaq: CYTH) has emerged as a significant player. The company recently announced encouraging preliminary safety data from its ongoing pivotal Phase 3 study, known as TransportNPC, along with a substudy targeting Niemann-Pick Disease Type C1 (NPC1). This milestone marks a critical step in the quest to address unmet medical needs faced by patients diagnosed with this rare genetic disorder. Understanding Niemann-Pick Disease Type C1 (NPC1)Niemann-Pic...
Gainesville, Fla. Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology firm committed to developing transformative medicines through cutting-edge scientific research, today announced a significant milestone in its quest to address neurodegenerative diseases. The European Patent Office has i...
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment in Phase 3 Trial for Niemann-Pick DiseaseIn the bustling biotech sector, every milestone achieved in clinical trials represents a leap forward in the quest to combat rare and debilitating diseases. Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company pioneering in the development of transformative therapies, has announced a significant milestone in its journey. The company has successfully completed the enrollment of the last patient in their pivotal Phase 3 TransportNPC trial, which targets systemic and neurological symptoms of Niemann-Pick Type C1 (NPC1) disease. Groundbreaking Trial: TransportNPCThe Tr...
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateIn a recent announcement, Cyclo Therapeutics, a clinical stage biotechnology company, shared its financial results for the first quarter of 2024 and provided a significant business update. The company, which is focused on developing life-changing medicines for patients and families living with diseases, outlined the progress made towards completing patient enrollment in their ongoing TransportNPC trial.The TransportNPC trial is a crucial endeavor for Cyclo Therapeutics, aiming to evaluate the potential of their innovative medicines. By developing therapies through science and innovation, the company hopes to provide ...
Cyclo Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company provides treatment for Niemann-Pick disease type C (NPC) under physician supervision through an FDA-approved Investigational New Drug protocol. The FDA grants orphan drug designation to drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the United States or where sales are unlikely to recover development costs. This designation offers benefits including tax credits and seven years of marketing exclusivity for the approved indication, which can affect the approval of competing products. The exclusivity applies solely to the designated indication and does not expedite the FDA review process. Additionally, the FDA offers expedited review programs such as fast track designation, accelerated approval, priority review, and breakthrough therapy designation to support drug development and approval.
Sources:
Cyclo Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cyclo Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cyclo Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
15.71 %